Answers are grounded in this paper and cite their sources.
Maple syrup urine disease (MSUD) is an inherited disorder of the branched-chain alpha-ketoacid dehydrogenase enzyme complex, which breaks down branched-chain amino acids (leucine, isoleucine, and valine). Deficiency in the activity of the enzyme complex causes an accumulation of leucine and ketoacids. Symptoms can include encephalopathy and central respiratory failure, likely due to a higher affinity for leucine over other amino acids and resultant uptake in the brain and nervous system. Elevated leucine can also cause renal sodium loss, resulting in cerebral edema. The disorder name comes from the distinctive and characteristic odor of maple syrup, which may be noticed in urine. Of note, families that are not culturally exposed to maple syrup may describe the odor as “sweet” or associate it with other breakfast foods. It is critical for the primary care clinician to understand that by the time this odor is detectable in an infant, the child is already in need of immediate evaluation and treatment. The severity of MSUD is inversely related to the amount of residual enzyme activity and can range from an attenuated (intermittently symptomatic) to a severe form. Without intervention in the first days of life, severe MSUD will result in vomiting, poor feeding, lethargy, irritability, and fluctuating muscle tone that can progress to encephalopathy and early death. In contrast, the attenuated form may present in the first months to years of life with mild symptoms (eg, altered levels of consciousness and ataxia)—or even no symptoms—during periods of illness but can progress to more severe decompensations if left untreated. There is also a form that is thiamine-responsive with symptoms that are minimized by large, therapeutic doses of thiamine.While MSUD is universally screened in all 50 states in the United States and the District of Columbia, every program has its own follow-up and referral processes. It is helpful for clinicians to become familiar with their state/territory’s newborn screening program website, program contact information, and follow-up processes.To confirm an abnormal newborn screening result for MSUD, all children with out-of-range results should be immediately (within 24 hours) referred to and evaluated by the closest available metabolic specialist who can assess the infant, order confirmatory testing, and provide access to appropriate metabolic nutrition support. Clinicians should contact the state newborn screening program for assistance with identifying the closest metabolic specialist if necessary. This is not a situation in which routine referrals or faxed/emailed communication are sufficiently expedient.Newborn screening assays for MSUD may target multiple analytes. Most programs detect an elevated leucine. Some also check for the presence of other branched-chain amino acids, alloisoleucine, related ratios, or some combination of these analytes. Even borderline abnormalities on newborn screening for MSUD may still warrant urgent referral to a metabolic specialist. With MSUD, amino acids begin to accumulate with the start of oral intake. Thus, amino acid levels may only be minimally elevated when the newborn screen is conducted at 24 hours of life, but will continue to rise precipitously with subsequent feeds.In most major metro areas, urgent evaluation by a metabolic specialist is available immediately and nearby. In some rural settings and states without metabolic centers, urgent evaluation may take greater effort to obtain. An infant with an out-of-range MSUD newborn screening result displaying any of the following symptoms suggestive of MSUD—poor feeding or poor weight gain, lethargy, “bicycling” or “fencing” movements, hypertonia, and/or a maple syrup odor—should be managed as a medical emergency and sent to an emergency department. If symptoms are ambiguous for MSUD, the clinician can test the infant’s urine for ketones. If urine ketones are present, the child must be emergently evaluated by a metabolic specialist.False positive screening results for MSUD may be more likely in the neonatal intensive care setting, especially among patients receiving total parenteral nutrition. However, a finding of alloisoleucine on a newborn screen reduces the likelihood of the result being a false positive and should prompt urgent evaluation.Parents or clinicians sometimes note a maple syrup-like odor in older infants and children. This semicommon cause for referral to geneticists rarely results in a diagnosis of MSUD. Outside of the newborn period, the detection of a maple syrup-like odor in a child who is well and eating and acting normally is not typically considered urgent. However, if the scent is noted to occur only during periods of illness or is accompanied by behavior changes, further evaluation by a metabolic specialist is recommended.Diagnostic testing for MSUD requires measurement of plasma amino acid levels. Children with MSUD will have elevations of branched-chain amino acids and the presence of alloisoleucine. In the case of attenuated forms, plasma amino acid testing results can be falsely negative unless performed when the affected individual is symptomatic.DNA testing should include BCKDHA, BCKDHB, and DBT genes. MSUD is generally an autosomal recessive condition, meaning affected individuals are born to parents who are both unaffected carriers (heterozygotes). Siblings of affected individuals have a 25% chance of being affected, a 50% chance of being an unaffected carrier, and a 25% chance of being unaffected and not a carrier.The goal of acute MSUD treatment is to achieve the most expedient reduction in serum leucine level possible to prevent or reduce the extent of encephalopathy. Acute management of a neonate with MSUD early involves immediate dietary replacement with a branched-chain amino acid-free medical formula. Additionally, titrated supplementation of isoleucine and valine is critical for anabolism promotion to prevent ongoing leucine buildup and because of their competitive inhibition with leucine for uptake into the brain. Symptomatic infants may require hemodialysis to rapidly decrease intoxicating amino acid accumulation.Chronic treatment of MSUD involves dietary management and monitoring of serum leucine levels. Attenuated disease management may be limited to having a “sick day” plan that families can implement whenever the child is ill. For severe disease, management includes ongoing adherence to a medical diet with isoleucine and valine supplementation under the supervision of a metabolic dietitian until the child receives a liver transplant. Liver transplantation restores whole-body branched-chain alpha-ketoacid dehydrogenase enzyme activity to levels sufficient to allow for an unrestricted diet with a decreased risk for decompensation. The thiamine-responsive form of MSUD responds well to thiamine supplementation, although usually some additional dietary intervention is still required. Developmental outcomes may depend on the timeliness of intervention and the number of metabolic crises experienced over time.Early diagnosis and treatment of MSUD, detected either by abnormal newborn screen or clinical symptoms, is of the utmost medical urgency to prevent disability or death. Involving experienced metabolic specialists, including metabolic dietitians, as soon as possible maximizes the chances for optimal outcomes.Comment: Sweet-smelling urine is a more common chief concern than I would expect based on the relative rarity of MSUD and the low odds that most caregivers are familiar with the condition. I imagine the reason so many children are brought in for this concern is that caregivers are very attuned to the way their children normally act, appear, and even smell. Small changes in a child’s or breastfeeding mother’s diet can subtly alter the child’s scent in ways that are readily apparent and may be alarming to a vigilant caregiver. While it is important not to miss a mild form of MSUD in a child beyond the neonatal period, as Ms Viall and Dr Tarini admonish, pediatricians should not rush to book an appointment for every child with sweet-smelling urine on a metabolic specialist’s limited schedule. Checking the child’s birth records to confirm normal newborn metabolic screening test results and ordering a new test when the original results cannot be verified are the preferred next steps.Linda Y. Fu, MD, MSAssociate Editor, In BriefThank you to Erin MacLeod, PhD, RD, LD, for her review and feedback.
No takes yet. Share an insight, caveat, or question.
Viall et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: